Australia’s TGA Moves Toward Greater Medical Device Transparency: What Industry Should Watch

What’s Changing?

Australia's Therapeutic Goods Administration (TGA) is consulting on proposed changes that would allow it to share more information with the public about medical devices following post-market reviews or investigations.

The consultation was published on 13 August 2026 and will remain open until 2 October 2026.

The proposal focuses on improving the TGA's ability to communicate information relating to the safety, quality, performance and use of medical devices, particularly when a device has been subject to regulatory review or investigation.

Importantly, these are proposed changes, not yet final regulatory requirements.

Why Is the TGA Proposing This?

The TGA explains that current legislative settings can limit the circumstances in which information about medical devices can be shared with external stakeholders who are not the manufacturer or sponsor.

Under the current framework, information generally cannot be shared unless specific legal conditions apply for example, where a legislative instrument permits disclosure, a regulatory decision has been made, or disclosure is necessary to facilitate safe use of a device.

The TGA says these limitations created challenges during the COVID-19 pandemic when timely information sharing about the safety and performance of certain medical devices was needed.

The proposed changes aim to address these constraints and provide greater transparency following post-market reviews and investigations.

What Could Change?

The consultation seeks feedback on proposals to expand the TGA's ability to lawfully release information under section 61 of the Therapeutic Goods Act 1989.

In particular, the TGA is asking stakeholders for views on:

• Whether information about medical devices involved in a post-market review or investigation should be shared with the public

• What types of information should be shared during or following such reviews or investigations

• How greater transparency could support public health and confidence in the regulatory system

The proposal is therefore not simply about publishing more information. It concerns the legal framework governing what information the regulator can disclose.

Who Should Pay Attention?

The consultation is particularly relevant to:

✔ Medical-device manufacturers

✔ Sponsors of medical devices in Australia

✔ International manufacturers operating through Australian sponsors

✔ Regulatory affairs teams

✔ Quality and compliance teams

✔ Companies managing post-market surveillance

✔ Organisations involved in medical-device safety and performance monitoring

For manufacturers and sponsors, the potential change is especially relevant because information arising from regulatory reviews could become more visible to healthcare professionals, patients and the broader public.

What Could Greater Transparency Mean for Industry?

If the proposed changes are implemented, manufacturers and sponsors may need to consider how their post-market regulatory strategies operate in an environment where more information could potentially become publicly available.

This reinforces the importance of maintaining robust systems for:

1. Post-Market Surveillance

Companies should maintain effective processes for identifying, assessing and responding to safety, quality and performance concerns.

2. Regulatory Communication

Manufacturers and sponsors should ensure that regulatory, quality and safety teams are aligned when responding to information requests or regulatory investigations.

3. Documentation

Clear and consistent documentation can become increasingly important when products are subject to regulatory review.

4. Risk Management

Companies should consider how potential safety or performance issues are identified, escalated and managed throughout the product lifecycle.

What Should Companies Do Now?

Monitor the Consultation

The proposed changes are still under consultation, so companies should not treat them as final requirements.

The consultation closes on 2 October 2026, after which submissions will be reviewed and outcomes made available through the TGA Consultation Hub.

Review Post-Market Systems

Companies can use this period to assess whether their existing post-market surveillance and regulatory communication processes are sufficiently robust.

Prepare for Greater Transparency

Manufacturers and sponsors should consider how they would manage communications if information arising from a post-market review or investigation becomes more widely accessible.

Follow the Final Outcome

The final regulatory position will depend on the consultation process and any subsequent legislative changes.

A Broader Regulatory Direction

The proposal forms part of Australia's broader effort to strengthen its medical-device regulatory framework and increase transparency.

The TGA links the proposed changes to An Action Plan for Medical Devices, which includes a patient-centred approach and greater public confidence in medical-device regulation.

The TGA also notes that greater transparency is consistent with the World Health Organization's Global Benchmarking Framework, which emphasises effective communication and transparency with healthcare professionals and the public.

This places Australia's proposal within a wider international regulatory movement toward greater transparency across the medical-device lifecycle.

ARQon Insight

For medical-device companies, regulatory intelligence is not limited to tracking new registration requirements.

Changes to post-market oversight, information disclosure and regulatory transparency can also influence how companies manage products after they enter the market.

Australia's latest consultation is a good example.

The proposal is still under development, but companies can already begin considering how increased transparency could affect their post-market surveillance, documentation, risk management and regulatory communication strategies.

The regulatory lifecycle doesn't end at market entry and neither should regulatory intelligence.

What This Means for Market Access

For international manufacturers entering Australia, market access increasingly requires consideration of the full medical-device lifecycle:

Market entry → Regulatory compliance → Post-market surveillance → Safety monitoring → Regulatory communication

A company may successfully obtain market authorization, but maintaining confidence in the product requires continued attention to safety, quality and performance.

The proposed changes therefore provide an important reminder that companies should integrate regulatory, quality and post-market functions rather than treating them as separate activities.

Key Takeaway

On 13 August 2026, the TGA opened consultation on proposed changes to improve information sharing about the safety, quality and performance of medical devices. The proposal would expand the regulator's ability to share information following post-market reviews or investigations.

The consultation remains open until 2 October 2026.

While the proposal is not yet a final regulatory requirement, it is an important development for manufacturers and sponsors to monitor particularly those operating in Australia's medical-device market.

For companies, the message is clear:

Strong post-market systems and regulatory transparency are becoming increasingly important components of sustainable market access.

How ARQon Can Support

ARQon supports healthcare and life-science companies with:

• Regulatory intelligence and monitoring

• Australia market-entry strategy

• Medical-device regulatory support

• Regulatory gap analysis

• Post-market regulatory planning

• Compliance strategy

• Cross-border market-access planning

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.